血管紧张素转换酶抑制剂会引发咳嗽。
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
作者信息
Yılmaz İnsu
机构信息
Department of Chest Diseases, Division of Immunology and Allergy, Erciyes University School of Medicine, Kayseri, Turkey.
出版信息
Turk Thorac J. 2019 Jan 1;20(1):36-42. doi: 10.5152/TurkThoracJ.2018.18014.
Abstract
Angiotensin-converting enzyme inhibitors (ACE-I) are widely used in diseases, such as hypertension, congestive heart failure, and myocardial infarction. Although these drugs are well tolerated, one out of five patients discontinues ACE-I due to drug side effects, mainly chronic cough. However, the pathogenesis of ACE-I-induced cough remains controversial and requires further study. In this review, the mechanisms that are suggested in ACE-I-induced cough pathophysiology will be discussed in detail in light of the current literature.
摘要
血管紧张素转换酶抑制剂（ACE-I）广泛应用于高血压、充血性心力衰竭和心肌梗死等疾病。尽管这些药物耐受性良好，但五分之一的患者因药物副作用（主要是慢性咳嗽）而停用ACE-I。然而，ACE-I引起咳嗽的发病机制仍存在争议，需要进一步研究。在这篇综述中，将根据当前文献详细讨论ACE-I引起咳嗽的病理生理学中所提出的机制。
相似文献
1
Angiotensin-Converting Enzyme Inhibitors Induce Cough.血管紧张素转换酶抑制剂会引发咳嗽。
Turk Thorac J. 2019 Jan 1;20(1):36-42. doi: 10.5152/TurkThoracJ.2018.18014.
2
Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure.血管紧张素转换酶抑制剂与咳嗽：高血压和充血性心力衰竭患者的前瞻性评估
J Clin Pharmacol. 1994 Nov;34(11):1116-20. doi: 10.1002/j.1552-4604.1994.tb01989.x.
3
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.1型血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂治疗高血压的比较。
J Hypertens Suppl. 1997 Dec;15(6):S31-6. doi: 10.1097/00004872-199715066-00007.
4
5
Angiotensin-converting enzyme inhibitor-induced angioedema.血管紧张素转换酶抑制剂诱发的血管性水肿。
Am J Med. 2015 Feb;128(2):120-5. doi: 10.1016/j.amjmed.2014.07.011. Epub 2014 Jul 21.
6
Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.血管紧张素转换酶抑制剂所致咳嗽：美国胸科医师学会循证临床实践指南
Chest. 2006 Jan;129(1 Suppl):169S-173S. doi: 10.1378/chest.129.1_suppl.169S.
7
Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.血管紧张素转换酶抑制剂及其对炎症、支气管反应性和咳嗽的影响。一项研究综述。
Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):369-80. doi: 10.1007/BF03259918.
8
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.在中国，血管紧张素转换酶抑制剂导致持续性咳嗽的发生率很高。
Br J Clin Pharmacol. 1995 Aug;40(2):141-4.
9
Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.血管紧张素转换酶基因插入/缺失多态性与心血管疾病：治疗意义
Drugs. 2002;62(7):977-93. doi: 10.2165/00003495-200262070-00001.
10
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?血管紧张素AT-1受体拮抗：在心血管和肾脏疾病中是ACE抑制的补充还是替代？
Expert Opin Pharmacother. 2002 Nov;3(11):1543-56. doi: 10.1517/14656566.3.11.1543.
引用本文的文献
1
WAO - ARIA consensus on chronic cough: Executive summary.世界变态反应组织-变应性鼻炎及其对哮喘的影响（WAO-ARIA）慢性咳嗽共识：执行摘要
World Allergy Organ J. 2025 Feb 24;18(3):101034. doi: 10.1016/j.waojou.2025.101034. eCollection 2025 Mar.
2
Molecular basis of human angiotensin-1 converting enzyme inhibition by a series of diprolyl-derived compounds.一系列二脯氨酰衍生化合物对人血管紧张素1转换酶抑制作用的分子基础
FEBS J. 2025 Mar;292(5):1141-1158. doi: 10.1111/febs.17384. Epub 2025 Jan 6.
3
Molecular insights into the inhibition of angiotensin-converting enzyme 1 by hemopressin peptides.血红加压素肽抑制血管紧张素转换酶 1 的分子机制研究。
Sci Rep. 2024 Nov 20;14(1):28726. doi: 10.1038/s41598-024-78893-3.
4
Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management.治疗策略中的相互作用：利钠肽与抑制中性肽链内切酶在高血压管理中的应用
Hypertens Res. 2025 Jan;48(1):284-300. doi: 10.1038/s41440-024-01989-w. Epub 2024 Nov 14.
5
Considering Adverse Effects of Common Antihypertensive Medications in the ED.考虑急诊科常见抗高血压药物的不良反应。
Curr Hypertens Rep. 2024 Aug;26(8):355-368. doi: 10.1007/s11906-024-01304-5. Epub 2024 Apr 30.
6
The pharmaco-epigenetics of hypertension: a focus on microRNA.高血压的药物-表观遗传学：以 microRNA 为重点。
Mol Cell Biochem. 2024 Dec;479(12):3255-3271. doi: 10.1007/s11010-024-04947-9. Epub 2024 Feb 29.
7
ACE inhibitors and their interaction with systems and molecules involved in metabolism.血管紧张素转换酶抑制剂及其与参与代谢的系统和分子的相互作用。
Heliyon. 2024 Jan 14;10(2):e24655. doi: 10.1016/j.heliyon.2024.e24655. eCollection 2024 Jan 30.
8
Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?心血管疾病的传统疗法与潜在的表观遗传药物：为何不兼而用之？
Life (Basel). 2023 Dec 22;14(1):23. doi: 10.3390/life14010023.
9
Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy.从豆类种子中获得的生物活性肽作为预防代谢综合征和饮食治疗的新化合物
Foods. 2022 Oct 21;11(20):3300. doi: 10.3390/foods11203300.
10
Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.血管紧张素转化酶抑制剂引起的咳嗽与安慰剂和其他抗高血压药物的比较：系统评价和网络荟萃分析。
J Clin Hypertens (Greenwich). 2023 Aug;25(8):661-688. doi: 10.1111/jch.14695. Epub 2023 Jul 7.
本文引用的文献
1
Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂治疗 2 型糖尿病成人高血压：我们为何青睐血管紧张素受体阻滞剂。
Can J Diabetes. 2018 Apr;42(2):118-123. doi: 10.1016/j.jcjd.2017.11.006. Epub 2017 Dec 22.
2
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?血管紧张素转换酶抑制剂在高血压中的应用：用还是不用？
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
3
Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials.血管紧张素转换酶抑制剂治疗期间咳嗽的发生率：一项随机安慰剂对照试验的荟萃分析。
Clin Pharmacol Ther. 2019 Mar;105(3):652-660. doi: 10.1002/cpt.1018. Epub 2018 Feb 8.
4
The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.年龄和性别对肾素-血管紧张素系统抑制剂所致咳嗽和血管性水肿报告的影响：VigiBase中的病例/非病例研究
Fundam Clin Pharmacol. 2017 Dec;31(6):676-684. doi: 10.1111/fcp.12313. Epub 2017 Sep 5.
5
Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.与血管紧张素转换酶抑制剂所致咳嗽相关的基因变异：瑞典人群的全基因组关联研究
Pharmacogenomics. 2017 Feb;18(3):201-213. doi: 10.2217/pgs-2016-0184. Epub 2017 Jan 13.
6
The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease.培哚普利所致血管紧张素转换酶抑制剂干咳在27492例血管疾病患者中的发生率及临床预测因素
Int J Cardiol. 2014 Oct 20;176(3):718-23. doi: 10.1016/j.ijcard.2014.07.108. Epub 2014 Aug 1.
7
Angiotensin-converting enzyme inhibitor-induced angioedema.血管紧张素转换酶抑制剂诱发的血管性水肿。
Am J Med. 2015 Feb;128(2):120-5. doi: 10.1016/j.amjmed.2014.07.011. Epub 2014 Jul 21.
8
Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.血管紧张素转换酶抑制剂引起的血管性水肿和咳嗽的药物遗传学：系统评价和荟萃分析。
Pharmacogenomics. 2013 Feb;14(3):249-60. doi: 10.2217/pgs.12.206.
9
Definitions and mechanisms of drug hypersensitivity.药物过敏反应的定义和机制。
Expert Rev Clin Pharmacol. 2010 Jul;3(4):539-51. doi: 10.1586/ecp.10.32.
10
Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis.血管紧张素转换酶和缓激肽基因多态性与咳嗽：一项荟萃分析。
World J Cardiol. 2011 Oct 26;3(10):329-36. doi: 10.4330/wjc.v3.i10.329.
Zotero 插件